CELC

Celcuity Inc.

16.76 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Celcuity Inc. stock is down -2.78% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 May’s closed higher than April. 100% of analysts rate it a buy.

About Celcuity Inc.

Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.

  • Stifel
    Thu May 16, 13:44
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 16, 11:44
    buy
    confirm
  • Craig-Hallum
    Thu May 16, 11:34
    buy
    initial
  • Needham
    Thu May 16, 06:39
    buy
    confirm